Cohort study of consistency between the compliance with guidelines for chemotherapy-induced nausea and vomiting and patient outcome
| Autor: | Masahiro Inoue, Kazunori Otsuka, Hiroyuki Shibata, Masatomo Miura, Naomi Shindo, Manabu Shoji |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Vomiting Nausea medicine.drug_class Emetogenicity Antineoplastic Agents Guidelines Cohort Studies Japan Neoplasms Internal medicine medicine Humans Antiemetic Pharmacology (medical) Adverse effect Aged Pharmacology business.industry Middle Aged Relative risk Anesthesia Chemotherapy-induced nausea and vomiting Female Patient-reported outcome Guideline Adherence medicine.symptom business Research Article Cohort study |
| Zdroj: | BMC Pharmacology & Toxicology |
| ISSN: | 2050-6511 |
| DOI: | 10.1186/s40360-015-0005-1 |
| Popis: | Background Chemotherapy-induced nausea and vomiting is one of the most influential factors that affect patient quality of life; thus, preventing this adverse event could lead to better patient outcome. Standard preventive guidelines for antiemetic treatment have already been established based on the emetogenicity of chemotherapeutic agents. It is important that compliance with in-house guidelines and their effect on patient outcome is monitored. Methods In 3 years since the Akita university hospital antiemetic guidelines were outlined, we assessed the incidence of chemotherapy-induced nausea and vomiting using the antiemesis tool of the Multinational Association of Supportive Care in Cancer. Compliance of the guidelines was extracted from the hospital clinical record, and the chemotherapy-induced nausea and vomiting was examined by the patient reported outcome. Results Seventy-three patients answered the questionnaire. The overall compliance rate with the guidelines for early nausea and vomiting was 98.6% and with the delayed nausea and vomiting was 87.7%. The complete response rate for the early and delayed chemotherapy-induced nausea and vomiting was 77.8% and 73.8%, respectively. The overall relative risk of early nausea and vomiting was 0.22 (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|